Boehringer Invests Big In The U.S. | Chemical & Engineering News
Volume 89 Issue 47 | p. 17 | Concentrates
Issue Date: November 21, 2011

Boehringer Invests Big In The U.S.

Department: Business
Keywords: active pharmaceutical ingredients, investment, R&D

Boehringer Ingelheim will spend $65 million to build an R&D center at its U.S. headquarters in Ridgefield, Conn. The facility will produce active pharmaceutical ingredients used in early development activities. Boehringer, a family-owned drug company based in Germany, says the facility brings the value of the capital investments it has made in the U.S. this year to $350 million. For example, the company is spending $100 million to expand a biologics plant in St. Joseph, Mo., and $42 million on a drug safety assessment building in Ridgefield.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment